𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The Relevance of Mouse Models to Understanding the Development and Progression of Human Breast Cancer

✍ Scribed by D. Craig Allred; Daniel Medina

Publisher
Springer US
Year
2008
Tongue
English
Weight
366 KB
Volume
13
Category
Article
ISSN
1083-3021

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Survey of genetically engineered mouse m
Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasis
✍ Susan Kasper πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 252 KB

Genetically engineered mouse models have been generated to study the molecular basis of prostate cancer (PCa) development, progression, and metastasis. Selection of a prostate-specific promoter, such as the probasin (PB) and prostate specific antigen (PSA) promoters, is critical for generating suffi

Inhibition of apoptosis in human breast
Inhibition of apoptosis in human breast cancer cells: Role in tumor progression to the metastatic state
✍ Yolanda FernΓ‘ndez; Bin Gu; Antonio MartΓ­nez; Angels Torregrosa; Angels Sierra πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 734 KB

Reduction in apoptosis has been associated with tumor metastases and response to chemotherapy in breast cancer. We examine the influence of apoptosis status and the expression of antiapoptotic proteins Bcl-2 and Bcl-x(L) on metastatic progression and response to therapy in an experimental model of b

Critical review of the models to study t
Critical review of the models to study the biologic progression of bladder cancer
✍ Dr. Jack A Schalken; Reindert J. A. Van Moorselaar; Pierre Paul Bringuier; FRANS πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 489 KB

For transitional cell carcinoma of the bladder, clinical data indicate that invasive, metastatic tumors can arise through at least two different progression pathways. The majority of invasive, metastatic bladder neoplasms clinically present de novo, i.e., the patients have no history of malignant bl